Embed Size (px)
Citation preview
JAN-25-2018 MON 01:32 P11 UH ARTS HUMANITIES FAX NO. 808 956 9085 P. 01/02
CoIlcg üí Ar1 and HumanitiesOffiei o th Dean
UNIVERSITYof friAWAI’I
MANOA
Public Testimony
January 24, 20 16
Undersigned DeansUniversity of l-lawai’i at Mãnoa
Board of RegentsUniversity of HawaiiBachrnan 2092444 Dole StreetHonolcilu, HI 96822
Regarding: Public Testimoni on Status of Design and Implementation Plan forSystem and UI-I Mänoa Orgarizational Changes and Consolidations to Improve theEfficiency and Effectiveness f Suppott Services
Deal’ Regent Randolph G. More:
We, the undersigned Deans et the University of Hawaii at Mnoa (UT-TM), welcomethe opportunity to testify abàut the ongoing discussions regarding UI-TM andorganizational changes.
We strongly endot’se Presidnt Lassner’s request that the Mãnoa Chancellor be aseparate position from that (the UH System President. The UI-TM requires strongand visionary leadership in dur endeavor to build our reputation as a globalresearch university that sim9ltaneously serves the needs of our students andcommunity. We urge you to support his intent to proceed with a search for aChancellor.
UI-TM is at a critical jLtncture, having undergone sharp budget constriction andtransitional leadership. We face structural budget challenges as well as deferredinvestments in academic programs and the campus’ physical infrastructure.Morale has suf’fered at muItile levels, as students, faculty, and our community haveindicated to us. The UI-TM reduires Strong leadership to address a myriad of issuesas the campus adapts to new fiscal realities and contemporary and changingeducational demands.
Against this backdrop, UI-TM requires leadership in a Chancellor to deliveroutstanding academic progrrns and innovative research.
2500 Campus Ruad, I Iawaii HaIl 302 HnnluIu, Hawal’I 9b822Telephunu: (OD1 956-64C0 Fax: (806) 956-9005
An Equal üppnr in ity/At0rnativu Action lnstitutinn
JAN—25—2016 MON 01:32 PM UH ART$ HUMANITIES FAX NO. 808 956 9085 P. 02/02
We further recommend that the UHM undergoes a process of reorganization todeliver more effective services. We recognize the benefits of streamliningadmjnisttation to better serve our students, promote researeft and serve the public.We acknowledge the need to be more accountable and to modernize our processesconcerning budget and acalemic planning.
We, the Deans, commit to working with a Chancellor and our faculty in a spirit ofshared governance to these ends:
• Align academic and student affairsa Upgrade functionality within human resources, fiscal, and campus and
facilities planning.a Review college and’school administration to promote efficient delivery of
modern academic programs
We ask yoct to support President Lassner’s request to proceed with a search for aChancellor. We are committed to a better UHM for our students, community, ands ta to.
1/26/2016 University of Hawaii Mail Written Testimony to the BOR Independent Audit Committee and full BOR
https://mail.google.com/mail/u/0/?ui=2&ik=5a046f4367&view=pt&search=inbox&msg=1528011036f751be&siml=1528011036f751be 1/1
Board of Regents <[email protected]>
Written Testimony to the BOR Independent Audit Committee and full BOR
Ioannis Stasinopoulos <[email protected]> Tue, Jan 26, 2016 at 12:32 PMTo: [email protected]
Dear Sir/Madam,
Below I attach written testimony that I ask be included as part of the record of the audit committee. As theCenter's grant coordinator responsible for monitoring the grants portfolio of UHCC Members and Faculty, Iask that my testimony be considered by the Audit committee and any upcoming full BOR meetingsdiscussing the UH Cancer Center.
The verbal testimony I wish to provide to the audit committee on 01/27/2016 is shown on page 2 of theattached PDF file.
Best Regards,
Ioannis Stasinopoulos, Ph.D.Research Grants CoordinatorUniversity of Hawaii Cancer Center701 Ilalo St., Rm 310Honolulu, HI 96813Tel: (808) 3565768Fax: (808) 5860115
BOR Testimony 012616IS_FINAL.pdf734K
University of Hawai‘i Cancer Center Grants Office
Table of Contents Page
Title Page and Table of Contents.......................................................................................................... 1 Verbal Testimony.................................................................................................................................. 2 Section A. Warbird – Navigant Report Error regarding UHCC Grants Portfolio..................................... 3 Section B. UHCC Faculty Cancer Grant Portfolio Comparison between 2016 and 2012....................... 4 Table 1: 2016 & 2012 UHCC Cancer Grant Funding Comparison......................................................... 4 Table 2: 2016 UHCC Cancer Grants Portfolio (Vetted by EAC in January 2016)................................... 5 Table 3: 2012 UHCC Cancer Grants Portfolio (Vetted by NCI in February 2012)................................... 11
UHCC Grants Office 01/26/2016
Page 1 of 16
Verbal Testimony
My name is Ioannis Stasinopoulos and I speak before you as the Center’s P30 Coordinator. Before coming to Hawai‘i in June 2013, I was a postdoctoral fellow and junior faculty at the Johns Hopkins University School of Medicine performing research on breast cancer.
A significant part of my work involves the monitoring of grants and publications awarded to the Center. In other words my job is to work together with the Director and the Senior Leaders to monitor our researchers’ productivity with respect to our designation.
University of Hawai‘i Cancer Center researchers are bringing more clinical, basic, and population science research funds than ever before.
The sponsor’s expectation is that our scientists translate nationally-competitive hypothesis-driven research into clinical, basic, and population interventions within our state, nationally, and beyond.
Significant progress is being made in these areas as evidenced by new grants and publications that continue the progress in cancer diagnoses, disparities, and underserved minority population cancer prevention and control.
Some examples of such research include:
Understanding of the cultural behaviors of the people of Hawai‘i that may pose barriers to vaccination against cervical cancer,
Large-scale efforts to understand the role of obesity in causing cancer in the multi-ethic populations,
The development of diagnoses for bladder and liver cancer,
The re-invigorated clinical research treatments made available to people who cannot travel to the mainland by the University of Hawai‘i Cancer Center.
In my written testimony I make available summary and detailed comparison tables showing our researchers’
cancer awards now and at the time of our last P30 renewal. The choice that faces the University and the state is stark: as you go through these grant awards one by one, I urge you to consider that following the loss of our designation the significant majority of this research will either be lost immediately or fade away after the divestment under consideration. If our Center does not gain additional support and loses the NCI designation, our most accomplished researchers who make positive impacts to our community will leave towards more supportive environments.
While the total funding brought in by our researchers has increased since 2012, so have the expectations for the renewal of our designation. The Center’s investigators annually apply to bring approximately $100 M of federal funds to the state of Hawai‘i. President Obama has recently announced a significant funding initiative to cure cancer. As the federal government makes more funds available, our designation enables our researchers to more successfully compete for the increasing funds. At this defining moment in the history of cancer research, the state of Hawai‘i and our flagship University must answer in a positive and forward looking way. Thank you for your time.
UHCC Grants Office 01/26/2016
Page 2 of 16
Section A. Warbird – Navigant Report Error regarding UHCC Grants Portfolio
To whom it may concern,
The Warbird - Navigant report1 regarding the UHCC business plan claims that UHCC faculty had 250 grants in FY13 and that this number dropped to 180 in FY15 (Appendix A, paragraph 7). However, in appendix E, paragraph 6, the consultant firm states that it “did not conduct a thorough financial review of selected individual
grants and awards, much less the entire portfolio”.
More importantly, publicly available UH reports show instead that in FY15 UHCC Faculty held 74 grants2, up 6 from FY13 when UHCC Faculty held 68 grants3. UH grant accounting numbers are consistent with internal UHCC grant office portfolio reporting required for the NCI designation and presented in pages 4-10 of this report.
As a comparison to our current relevant grants portfolio we provide the Center’s 2012 grants tables, as reviewed by the NCI, at the time of the Center’s last competing renewal in 2012.
We therefore ask all interested parties to disregard the Warbird – Navigant grant count as erroneous.
1. http://www.hawaii.edu/offices/bor/audit/materials/201601271400/III.A.1._University_of_Hawaii_at_Manoa_Cancer_Center_Report_and_Business_Plan.pdf
2. http://www.ors.hawaii.edu/files/2015_Annual_Report_Extramural_Awards&Expenditures.pdf 3. http://www.ors.hawaii.edu/files/2013_Annual_Report_Extramural_Awards&Expenditures.pdf
UHCC Grants Office 01/26/2016
Page 3 of 16
Section B*. UHCC Faculty Cancer Grant Portfolio** Comparison between 2016 and 2012
*Detailed grant tables shown in section B represent those awards that the designated Research Program Directors and Administration have agreed as bearing relevance to cancer.
** The tables below show the annual funding income of cancer grants active on 12/01/15 and 12/31/11 vetted during the Center’s External Advisory Committee (EAC) annual site visit in January, 2016 and the National Cancer Institute’s (NCI) review and evaluation in February, 2012, respectively.
Table 1: 2016 & 2012 UHCC Cancer Grant Funding Comparison
2016 UHCC Faculty Cancer Grant Funds: $22,713,574
2012 UHCC Faculty Cancer Grant Funds: $19,878,036
UHCC Grants Office 01/26/2016
Page 4 of 16
Table 2: 2016 UHCC Cancer Grants Portfolio (Vetted by EAC in January 2016)
PrincipaI Investigator
Specific Funding Source
Project Number Project Start Date
Project End Date
Project Title Annual
Project Total Costs ($)
Owen J (PAVIR) Bantum E
NCI VIR-Palo Alto 7R21CA166029-02 9/26/2013 8/31/2016 Impact of Social Networking on Dose and Effects of
Cancer Survivorship Trials
96,246
Berenberg J Morris P NCI 5UG1CA189804-02 8/1/2014 7/31/2019 Hawai'i Minority /Underserved NCORP
748,896
Carbone M NCI 1R01CA198138-01 7/6/2015 6/30/2020 Germline Bap1 Mutations And Malignant Mesothelioma: Mechanisms And Early Detection
349,988
Fagan P NIDA VCU 5P50DA036105-03 9/1/2015 8/31/2017 PROJECT 4: Quantitative And Qualitative Methods For MRTP Evaluation P219-245
90,172
Fei P NCI 5R01CA136532-06 7/1/2009 5/31/2016 Roles of Fanconi Anemia Pathway in Bladder Tumorigenesis
141,979
Fei P NCI 5R01CA188251-02 7/1/2014 6/30/2019 Molecular Insights into the Fanconi Anemia Tumor Suppressor Signaling Pathway
317,475
Franke A NCI Vanderbilt University 5R03CA189455-02 9/1/2015 8/31/2016 Effect of Magnesium treatment on Vitamin D Resistance
20,711
Ward W Garmire L NIGMS 2P20GM103457-06A1 7/1/2014 6/30/2019
Project 3: Linking Maternal Obesity And Offspring Cancer Risks Through Integration Cord Blood Stem Cell Methylome And Transcriptome
267,750
Hedges J NCI 5P30CA071789-16 7/1/1994 6/30/2017 University of Hawaii CCSG 1,361,692
Hedges J NCI 3P30CA071789-16S1 7/1/1994 6/30/2017 University of Hawaii CCSG 114,745
Hedges J NCI 3P30CA071789-16S2 7/1/1994 6/30/2017 University of Hawaii CCSG 650,078
Hedges J NCI 3P30CA071789-16S3 7/1/1994 6/30/2017 University of Hawaii CCSG 177,700
Hernandez B NCI JHU 5R01CA140311-05 4/19/2011 3/31/2016 Multicenter Genetic, Epigenetic & Expression Analysis of DCIS Outcome Predictors
5,000
UHCC Grants Office 01/26/2016
Page 5 of 16
Hernandez B NCI HHSN26100004 8/15/2015 8/14/2016 Patterns Of Care/Quality Of Care Study: Diagnosis Year 2014
52,508
Hernandez B NCI HHSN261201300009I 8/1/2013 7/31/2017 Surveillance, Epidemiology, And End Results (SEER) 1,724,464
Hernandez B NCI HHSN261201300009I-3937521 9/17/2015 9/16/2017 SEER-linked Virtual Tissue Repository (VTR)
138,367
Jia W NCI 1U01CA188387-01 8/1/2015 7/31/2020 Gut Microbiota Mediated Bile Acid Alterations In Hepatic Carcinogenesis
536,813
Kwee S Okimoto G NCI 5R01CA161209-05 7/1/2011 4/30/2017 Functional Genomics and Molecular Imaging of Liver
Disease and Cancer
411,672
Le Marchand L Haiman C (USC) NHGRI USC 5U01HG007397-03 9/1/2013 5/31/2017 Epidemiologic Studies Of Putative Functional Variation
In Multiethnic Cohort
198,468
Le Marchand L NCI University of Minnesota 5P01CA138338-05 4/1/2010 3/31/2016 Multiethnic Genome Scan Of Metabolic Phenotypes
451,684 Le Marchand L Haiman C Wilkens L
NCI 5U01CA164973-04 9/1/2012 8/31/2017 Understanding Ethnic Differences In Cancer: The Multiethnic Cohort Study
3,879,211
Le Marchand L NCI Stanford 5UM1CA167551-03 5/1/2013 4/30/2018 Colon Cancer Family Registry Cohort 132,713
Le Marchand L NCI 5P01CA168530-04 9/1/2012 8/31/2017 Obesity, Body Fat Distribution, And Cancer Risk In The Multiethnic Cohort
4,121,831
Lim U NIDDK 1R21DK105413-01 9/1/2015 8/31/2017 Brain-Gut Microbiome-Visceral Adiposity Relationships In Multiethnic Adults
237,470
Loo L NCI 5R21CA176555-02 7/8/2014 6/30/2016 Obesity And Igf-Axis Activation In Native Hawaiian Women With Breast Cancer
199,665
Matter M NIGMS 5R01GM104984-04 9/1/2012 8/31/2017 Regulation of Endothelial Permeability in Sepsis 330,568
Park S NCI Health Research Inc. 5P01CA151135-05 8/1/2011 7/31/2016 Epidemiology Of Breast Cancer Subtypes In African
American Women: A Consortium
32,699
Ramos J Ji J NCI 5R01CA096841-10 8/1/2002 4/30/2016 Regulation of Tumor Promotion by RASGRP1 284,811
UHCC Grants Office 01/26/2016
Page 6 of 16
Rosser C NCI Nonagen Bioscience Corporation
5R44CA173921-03 8/6/2013 2/29/2016 Development of Molecular Assays for Non-Invasive Bladder Cancer Detection
37,500
Turkson J NCI 5R01CA161931-04 8/1/2012 5/31/2017 Salicylic acid-based small-molecule STAT3 inhibitors for anticancer therapy
480,634
Vogel C Palafox N Ward D NCI 2U54CA143727-06 9/28/2009 8/31/2020 University of Guam/Cancer Research Center of Hawaii
Partnership (1 of 2)
1,015,895
Wilkens L
NCI Cancer Prevention Institute of California
7R01CA154644-03 9/1/2011 8/31/2016 Obesogenic Environment: Impact On Breast, Colorectal, And Prostate Cancer Risk
11,271
Wills T Gibbons F NCI 5R01CA153154-05 7/1/2010 4/30/2016 Self-Control as a Moderator for Effects of Mass Media on Adolescent Substance Use
87,010
Wills T Ernst T NIDA 1U01DA041117-01 9/30/2015 5/31/2016 Adolescent Brain Cognitive Development (ABCD) Prospective Research in Studies of Maturation (PRISM) Consortium
1,388,507
Wills T NCI Dartmouth College 2R01CA077026-15A1 9/30/1997 4/30/2018 Visual Media Influences on Adolescent Smoking
Behavior
42,393
Yang H DOD W81XWH-13-1-0175 8/1/2013 7/1/2016 Mesothelioma: Identification of the Key Molecular Events Triggered by BAP1
50,782
Yang H NCI 5R01CA160715-05 7/28/2011 5/31/2016 The Role of HMGB1 in the pathogenesis of Mesothelioma
311,250
Yu H NCI 5R01CA138698-05 8/1/2010 5/31/2016 Epidemiologic Study Of Hepatocellular Carcinoma In The US
1,460,631
Garmire L NIEHS 1K01ES025434-01 9/29/2014 6/30/2019 An Integrative Bioinformatics Approach To Study Single Cancer Cell Heterogeneity
180,368
Carbone M Yang H
The V Foundation N/A 10/31/2012 10/1/2016 HMGB1, A Biomarker for Mineral Fiber Exposure and
Detection of Malignant Mesothelioma $23,835
Garmire L Hawaii Community Foundation
14ADVC-64566 5/15/2014 11/14/2016 Using Next Generation Sequencing Technology To Detect Circulating MicroRNAs As Diagnostic Biomarkers Of Liver Cancer
$16,942
Ramos J Hawaii Community Foundation
15ADVC-74405 5/11/2015 11/10/2016 PEA-15 Regulation of Endocytic Trafficking in Cancer 32,270
UHCC Grants Office 01/26/2016
Page 7 of 16
Matter M
Myra W. and Jean Kent Angus Foundation
115054959 9/23/2015 9/15/2016 The Role of Bit1 in Neuroblastoma 53,000
Acoba J Biothera BT-CL-PGG-CRC1031 5/30/13 6/30/2020
A Phase 3 Open Label Randomized, Multicenter Study Of Imprime PGG In Combination With Cetuximab (Erbitux) In Subjects With Recurrent Of Progressive KRAS Wild Type Colorectal Cancer
31,191
Acoba J Eli Lilly 13X-MC-JHTC 4/22/2013 4/21/2017 A Phase I Study Of LY2784544 Testing Alternative Dosing Regimens In Patients With Myeloproliferative Neoplasms
31,256
Acoba J Sanofi OB13597 10/24/2014 6/30/2019
Prospective International Observational Cohort Non-Comparative Study Describing The Safety And Effectiveness Of ZALTRAP Administered In Combination W/ FOLFIRI For The Treatment Of Patients W/ Metastatic Colorectal Cancer...
11,741
Acoba J Novartis CLEE11XUS03 2/26/2015 12/31/2017
Modular Phase II Study To Link Targeted Therapy To Patients W/ Pathway Activated Tumors: Module 8 - Lee011 For Patients W/ Cdk4/6, Cyclin D1/3 Or P16 Activated Tumors
3,213
Acoba J Pfizer A8641019 7/31/2014 12/31/2017
Phase 1/2 Study of PF-03084014 in Combination with Gemcitabine and Nab-Paclitaxel in patients with previously untreated Metastatic Pancreatic Ductal Adenocarcinoma
22,086
Carney M Amgen/Gynecological Oncology Group
GOG 3001, 806-01 2/14/2013 10/30/2017
Amgen: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Of AMG 386 With Paclitaxel And Carboplatin As First-Line Treatment Of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal Or Fallopian Tube Cancer
61,118
Carney M AstraZeneca/Gynecological Oncology Group
GOG 3004, D0818C00001 4/10/2014 3/27/2017
A Phase III, Randomized, Double Blind, Placebo Controlled, Multicentre Study Of Olaparib Maintenance Monotherapy In Patients With BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer Following First Line Platinum Based Chemotherapy, D0818C00001
36,959
Cho J Polaris CRCH-1104 11/3/2011 9/30/16
A Randomized, Double-Blind, Multi-Center Phase 3 Study Of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC In Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy
36,238
Cho J Onconova AGICC 11PAN01 1/18/2012 9/30/2016 Phase II/III Stdy Eff & Sfty Of Gem 40,091
Cho J Gennentech Roche BO22589 4/7/2011 6/1/2016 Phase III Eval The Sfty Of T-Dm1
540
Chong M Prometheus 10PLK13 6/21/2015 6/20/2020 Proleukin Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
-
UHCC Grants Office 01/26/2016
Page 8 of 16
Fukumoto J Millennium C16014 1/29/2015 8/6/2019
A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 + Lenalidomide & Dexamethasone Vs. Placebo + Lenalidomide & Dexamethasone In Adult Patients W/ Newly Diagnosed Multiple Myeloma
21,905
Fukumoto J Bristol Myers-Squib CRCH-1101 12/13/2011 6/30/2016
Studying Interventions For Managing Patients With Chronic Myeloid Leukemia In Chronic Phase: The 5-Year Prospective Cohort Study (BMS SIMPLICITY)
5,620
Miyashiro M Jarrod Holmes ML25749 1/6/2014 11/29/2016
Combination Immunotherapy With Herceptin And The HER2 Vaccine E75 In Low And Intermediate HER2-Expressing Breast Cancer Patients To Prevent Recurrence
-
Miyashiro M PUMA Biothechnology PUMA-NER-1301 2/28/2014 3/9/2019
A Study Of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine In Patients With HER2+ Metastatic Breast Cancer Who Have Received Two Or More Prior HER2 Directed Regimens In The Metastatic Setting
29,742
Rosser C Altor BioScience CA-ALT-803-01-14 8/20/2014 6/27/2019 A Study Of Intravesical Bacillus Calmette-Guerin (BCG) In Combination With Alt-803 In Patients With BCG-Naive Non-Muscle Invasive Bladder Cancer
43,786
Rosser Bayer Reassure 16913 4/15/2015 4/17/2020 REASSURE - Radium-223 alpha Emitter Agent in Safety Study in mCRPC popUlation for long-teRm Evaluation
-
Tamura D Exelixis XL184-309 4/23/2014 4/2/2019
A Phase 3, Randomized, Double-Blind, Controlled Study Of Cabozantinib (XL184) Vs. Placebo In Subjects W/ Hepatocellular Carcinoma Who Have Received Prior Sorafenib
45,924
Wilkinson R
Millennium Pharmaceuticals/Children's Hospital of Philadelphia (CHOP)/Children's Oncology Group (COG)
AAML1031 4/11/2013 4/11/2023
A Phase III Randomized Trial For Patients With Senovo AML Using Bortezomib (NSC# 681239) And Sorafenib (BAY 43-9006, NSC# 724772) For Patients W Allelic Ratio FLT3/ITD
-
Wilkinson R
Millennium Pharmaceuticals/Children's Hospital of Philadelphia (CHOP)/Children's Oncology Group (COG)
AALL07P1 2/15/2012 2/15/2022 A Phase II Pilot Trial Of Bortezomib (PS-341, VELCADE IND 58,443) In Combination With Intensive Re-
-
Wilkinson R
Hoffmann-La Roche/Children's Hospital of Philadelphia (CHOP)/Children's Oncology Group (COG)
ANHL1131 2/15/2012 2/15/2022 Induction Therapy For Children With Relapsed Acute Lymphoblastic Leukemia (ALL) And Lymphoblastic
9,000
UHCC Grants Office 01/26/2016
Page 9 of 16
Wilkinson R
Bristol-Myers Squibb Company/Children's Hospital of Philadelphia (CHOP)/Children's Oncology Group (COG)
BMS CA180-372 (COG-AALL1122) 4/5/2013 4/5/2023 Lymphoma (LL)
-
Wilkinson R
Children's Hospital of Philadelphia (CHOP)/Children's Oncology Group (COG)/Sanofi/Genzyme
AALL1131-Sanofi/Genzyme 2/23/2015 1/3/2017
Intergroup Trial For Children Or Adolescents With B-Cell NHL Or B-AL: Evaluation Of Rituximab Efficacy And Safety In High Risk Patients
15,500
Totals 22,713,574
UHCC Grants Office 01/26/2016
Page 10 of 16
Table 3: 2012 UHCC Cancer Grants Portfolio (Vetted by NCI in February, 2012)
Principle Investigator
Funding Agency
Grant Number Start Date
End Date
Project Title Annual
Project Total Costs ($)
Albright, Cheryl L NCI 5R01 CA115614-04 09/29/07 07/31/12 Physical Activity in Women with Infants -
Albright, Cheryl L NCI 3R01CA115614-03S1 08/01/09 07/31/12 Administrative Supplements for: Physical Activity in Women with Infants -
Albright, Cheryl L NIDA/Klein Buendel, Inc. 5R42DA031402-03 01/01/08 08/31/13 A Home Exercise Program for Women with Infants and
Young Children 39,000
Ambrosone, Christine (HRI)/ Kolonel, Laurence (UHCC)
NCI 1P01CA151135-01A1 08/01/11 07/31/16 Epidemiology of Breast Cancer Subtypes in African American Women: A Consortium 32,366
Amos, Christopher (MD Anderson)/ Le Marchand, Loic (UHCC)
NCI 1U19CA148127-01 07/09/10 06/30/14 Transdisciplinary Research in Cancer of the Lung (TRICL) 188,824
Bachmann, Andre NCI 5R01CA111419-04 REV 08/01/06 06/30/12 Role of Polyamines in MYCN-Amplified Neuroblastoma -
Bachmann, Andre Hawaii Community Foundation
09ADVC-45411 11/04/09 05/05/12 In Vivo Efficacy of Novel Proteasome Inhibitors in Neuroblastoma -
Berenberg, Jeffrey NCI 5U01CA063844-18 08/01/94 05/30/15 Hawaii Minority-Based Clinical Community Oncology Program 542,939
Berenberg, Jeffrey Southwest Oncology Group CA37429 05/18/07 05/31/13 Southwest Oncology Group Purchase Services Agreement:
SELECT & Ancillary Studies 22,900
Carbone, Michele NCI 5P01CA114047-05 09/15/06 08/31/12 Pathogenesis of Mesothelioma -
Carbone, Michele NCI 3P30CA071789-12S9 07/01/97 06/30/12 Cancer Research Center of Hawaii 720,185
Carbone, Michele NCI 3P30CA071789-12S6/ARRA 09/28/09 09/27/12 Cancer Research Center of Hawaii -
Carbone, Michele NCI 3P30CA071789-12S7/ARRA 09/30/09 09/28/12 Cancer Research Center of Hawaii -
Cheng, Iona NCI 5R01CA140636-03 09/28/09 07/31/13 Characterizing Mitochondrial NDA Susceptibility to Breast, Colorectal, and Prostate Cancer 467,992
Cheng, lona NCI 1R01CA154644-01 09/01/11 07/31/15 Obesogenic Environment: Impact on Breast, Colorectal, and Prostate Cancer Risk 344,827
Cheng, lona The V Foundation MISC 2009VScholar 11/01/09 10/31/12 Identifying IGF1 Genetic Susceptibility Variants for Prostate
Cancer in African Americans -
UHCC Grants Office 01/26/2016
Page 11 of 16
Cho, Jonathan K Genentech, Inc. CRAProt B022589/TDMI4788G 11/02/10 11/01/13 A Randomized, 3 Arm, Multicentre, Phase III Study to
Evaluate the Efficacy and the Safety of T-DM1C 160,806
Cho, Jonathan K Onconova Therapeutics N/A 10/01/11 09/30/13
A Phase ll/lll, Multi-Center, Randomized, Controlled Study to Compare the Efficacy and Safety of Gemcitabine Alone vs. ON 01910.Na Combine with Gemciitabine in Patients with Previously Untreated Metastatic Pancreatic Cancer" Protocol Number 04-22
13,495
Cho, Jonathan K Polaris N/A 11/03/11 09/30/13 A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Case (BSC) Versus Placebo Plus BSC
48,639
Chu, Wen-Ming NIAIDS 7R01AI054128-07 04/01/09 03/31/14 Mechanism of Activation of Innate Immunity by ISS-DNA 330,785
Fei, Peiwen NCI 7R01CA136532-04 07/01/09 05/31/14 Roles of the Fanconi Anemia Pathway in Bladder Tumorigenesis 285,246
Gaudino, Giovanni
Hawaii Community Foundation
10ADVC-47420 09/01/10 09/01/12 Role of tumor necrosis factor (TNF) signaling in chrysotile-asbestos induced mesothelioma 100,000
Goodman, Marc NCI 2R01 CA058598-13 08/15/93 05/31/13 Collaborative Genetic Study of Ovarian Cancer Risk 482,794
Goodman, Marc NCI HHSN261201000037C AMDT 0001 10/01/14 09/30/15 Patterns of Car/Quality Care Diagnosis Year 2009 47,222
Goodman, Marc NCI HHSN261201000171 03/19/10 03/18/12 The Cancer Genome Atlas (TCGA) 146,529
Goodman, Marc NCI HHSN261201000171 MOD 0001 03/19/10 03/18/12 The Cancer Genome Atlas (TCGA) 47,536
Goodman, Marc NCI HHSN261201000037C AMDT2 08/01/11 07/31/12 Surveillance, Epidemiology and End Results (SEER) 1,207,758
Hannun, Yusuf (MUSC) / Kawamori, Toshihiko (UHCC)
NCI 5P01CA097132-09 07/01/02 07/31/13 Sphingolipids in Cancer Biology and Therapy 15,837
Hecht, Stephen (UMN)/ Le Marchand, Loic (UHCC)
NCI 5P01C A138338-02 04/01/10 03/31/15 Mechanisms of Ethnic/Racial Differences in Lung Cancer Due to Cigarette Smoking 78,256
Henderson, Brian (USC)/ Le Marchand, Loic (UHCC)
NCI U01 CA098758-08 06/05/03 07/31/12 Characterizing Genetic Susceptibility to Breast and Prostate Cancer; the BPC3 63,271
Henderson, Brian (USC)/ Le Marchand, Loic (UHCC)
NCI U01 CA136792-03 03/25/09 02/28/12 A Genome Wide Association Study of Prostate Cancer in African Americans; Subaward from USC 203,957
Hernandez, Brenda
Association of American MM-1132-10/10 09/30/09 09/29/12 Evaluation of genital self-sampling for HPV detection in males -
UHCC Grants Office 01/26/2016
Page 12 of 16
Medical Colleges
Herzog, Thaddeus NCI 5R01CA120799-05 09/27/07 07/31/12 Testing Alternative Stage Models of Smoking Cessation: An Intervention Study 221,160
Kawamori, Toshihiko NCI 5R01CA124687-05 01/01/09 12/31/13 The Sphingolipid Pathway in Colon Cancer Chemoprevention 271,722
Kolonel, Laurence NCI 5R37CA054281-19 01/01/83 02/28/13 Multiethnic Cohort Study of Diet and Cancer (VDPP: Rarer Cancers) 2,285,139
Kolonel, Laurence NCI 3R37CA54281-17S1 09/01/09 08/31/12 Multiethnic Cohort Study of Diet and Cancer; Administrative Supplement -
Kolonel, Laurence NCI 5P01CA33619-22 01/01/83 08/31/12 Molecular Epidemiology of Nutrition and Cancer in the Multiethnic Cohort Study -
Kwee, Sandi NCI 5R21CA139687-02 07/01/09 06/30/12 Treatment Effects on tumor 18F-Choline Metabolism in Advanced Prostate Cancer -
Kwee, Sandi (QMC) / Okimoto, Gordon (UHCC)
NCI 1R01CA161209-01 07/01/11 04/30/16 Functional Genomics and Molecular Imaging of Liver Disease and Cancer 452,004
Kwee, Sandi (QMC) / Okimoto, Gordon (UHCC)
NCI 1R01CA161209-01 07/01/11 04/30/16 Functional Genomics and Molecular Imaging of Liver Disease and Cancer
Kwee, Sandi (QMC)/ Okimoto, Gordon (UHCC)
NCI 1R01CA161209-01 07/01/11 04/30/16 Functional Genomics and Molecular Imaging of Liver Disease and Cancer
Lau, Alan Hawaii Community Foundation
11ADVC-49235 05/18/11 11/18/12 Regulating the Degradation of Connexin43 Through the Proteasomal Pathway 50,000
Le Marchand, Loic NCI 5U24CA074806-13 06/25/97 08/31/12 The Colon Cancer Family Registry: Hawaii 425,502
Le Marchand, Loic NCI 5R01CA126895-04 09/01/08 07/31/13 Whole Genome Scan for Modifier Genes in Colorectal Cancer 1,853,251
Le Marchand, Loic NCI 5R01CA129063-04 09/15/08 07/31/12 Inflammation and Innate Immunity Genes and Colorectal Cancer Risk 565,702
Le Marchand, Loic NCI 3R01CA126895-02S1 09/30/09 09/29/12 Whole Genome Scan for Modifier Genes in Colorectal Cancer -
Le Marchand, Loic NHGRI 5U01HG004802-04 07/01/08 05/31/12 Epidemiology of Putative Causal Variants in the Multiethnic Cohort 1,599,270
Le Marchand, Loic NHGRI 3U01HG004802-02S1 09/30/09 08/31/12 Epidemiology of Putative Causal Variants in the Multiethnic Cohort; Supplement -
Le Marchand, Loic World Cancer Research Fund RFA09-149 07/01/10 06/30/13 Validation of the Hair as a Tissue to Biomonitor PhIP, a
Carcinogenic Heterocyclic Aromatic Amine 577,394
Lim, Unhee AICR 09A143 01/01/10 12/31/11 Dietary Intake of Choline and Betaine, Related Genetic Polymorphisms and the Rick of CRC 165,000
Lindor, Noratane (Mayo Clinic)/ Le NCI 3U24CA074800-11S1 09/01/09 08/31/12 The Familial Colorectal Neoplasia Collaborative Group/
Subward Agree. Mayo Clinic Rochester 6,836
UHCC Grants Office 01/26/2016
Page 13 of 16
Marchand, Loic (UHCC)
Lorenzo, Patricia NCI 2R01CA096841-06A2 08/01/02 04/30/16 Regulation of Tumor Promotion by RasGRPI 284,811
Lorenzo, Patricia NCI 1R03C A165128-01 12/01/11 11/30/13 Ras Activation Pathways in UVR-lnduced Epidermal Transformation
75,000
Lorenzo, Patricia Hawaii Community Foundation
09ADVC-45412 11/04/09 11/04/11 Mechanistic and structural studies of the fungal derivative terspetacin as an antiangiogenic agent - CRCH -
Maskarinec, Gertraud NCI 5R01CA080843-09 09/01/99 02/28/12 Effects of Soy on Estrogens in Breast Fluid and Urine -
Maskarinec, Gertraud NCI 1R03 CA135699-02 03/01/09 02/28/12 A Pooled Analysis of Mammographic Density and Breast
Cancer -
Maskarinec, Gertraud NCI 1R03CA150041 -02 04/01/10 03/31/12 Urinary Estrogen Metabolites in A 2-Year Soy Trail Among
Premenopausal Women 66,300
Matter, Michelle Hawaii Community Foundation
11ADVC-49236 05/18/11 11/18/12 Bit-1 Signaling in Cardiovascular Disease 50,000
Owen, Jason (LLU)/ Bantum, Erin (UHCC)
NCI 1R21CA143642-02 08/05/10 07/31/12 Use of Natural Language Processing to Identify Markers of Coping 60,050
Ramos, Joe NIGMS 5R01GM088266-02 09/30/10 08/31/14 RSK2 regulates integrin-mediated adhesion and migration 282,150
Ramos, Joe Hawaii Community Foundation
09AVSBGF-44279 05/27/09 12/31/11 RSK2 modulates cell adhesion -
Ryazanov, Alexey (UMDNJ)/ Fleig, Andrea (UHCC)
NIGMS 5P01GM078195-04 05/01/07 04/30/12 Regulation of metal ion homeostasis by channel kinases 391,600
Sargent, James (Dartmouth)/ Wills, Thomas (UHCC)
NCI R01CA077026 05/01/11 04/30/12 Visual Media Influences on Adolescent Smoking Behavior 35,132
Sargent, James (Dartmouth)/ Wills, Thomas (UHCC)
NIAAA 2R01AA015591 08/01/10 07/31/12 Media Influences on Early Onset Alcohol Use 35,779
Simons, Jeffrey (USD)/ Wills, Thomas (UHCC)
NIAAA 1R01AA17433-01A2 06/01/09 05/31/12 Self-Control and Alcohol Problems: Psychological Mechanisms -
Sumida, Kenneth NSABP Foundation TIND-118 12/01/97 01/31/13 NSABP Foundation - Master 118 RCUH 60,000
Sumida, Kenneth NSABP Foundation TIND118-B43 12/01/07 01/31/13 Addendum to TIND -118 Industrial Master Purchased
Services Agreement, Subpart B-43: GENENTECH 21,600
UHCC Grants Office 01/26/2016
Page 14 of 16
Tsai, Naoky NIH 5U01DK082863-02 09/30/08 05/31/15 Hepatitis B Clinical Research Network Clinical Center Michigan-Hawaii Consortium 401,256
Turesky, Robert (Wadsworth Center)/ Le Marchand, Loic (UHCC)
NCI 5R01CA122320-05 09/11/07 07/31/12 Chemical Markers of Heterocyclic Aromatic Amines for Human Biomonitoring; Subaward from Health Research, Inc. 50,579
Turkson, James NCI 7R01CA128865-04 09/01/08 07/31/12 Therapeutic Application of Novel Stat3 Inhibitors in Breast and Pancreatic Cancers 223,913
Ulrike, Peters (FHCRC)/ Le Marchand, Loic (UHCC)
NCI 5U01CA137088-03 08/14/09 07/31/13 Colorectal Cancer Genome-Wide Associations Studies Consortium/ Subaward Fred Hutchinson Cancer Research Center
121,157
Vogel, Carl-Wilhelm NCI 5U54CA143727-03 09/28/09 08/31/14 University of Guam/Cancer Research Center of Hawaii
Partnership 859,531
Vogel, Carl-Wilhelm NCI 3U54C A143727-02S1 09/28/09 08/31/14 University of Guam/Cancer Research Center of Hawaii
Partnership Supplement -
Wada, Randy Hawaii Community Foundation
47026 06/08/10 12/08/11 Analysis of MYCN regulation by chromosome conformation capture 50,000
Wada, Randy AICR 09A018-REV2 01/01/10 12/31/11 Regulation of the MYCN Oncogene in Neuroblastoma 165,000
Wilkinson, Robert
Kapiolani Clinical Research Center
CRA 07/01/10 06/30/12 Cooperative Research Agreement between Kakpiolani Medical Center for Women & Children and University of Hawaii Cancer Research Center of Hawaii
171,232
Wills, Thomas NCI 5R01CA153154-02 07/01/10 04/30/15 Self-Control as a Moderator for Effects of Mass Media on Adolescent Substance use 608,245
Wills, Thomas NIDA 5R01DA021856-05 09/30/07 06/30/12 The Project Success Model: Evaluation of A Tiered Intervention 646,328
Yang, Haining NCI 1R01CA160715-01 07/28/11 05/31/16 The Role of HMGB1 in Pathogenesis of Mesothelioma 311,250
Yang, Haining HCF - Leahi Fund 08PR-42589 09/24/08 12/31/11 Mesothelioma Prevention and Early-Detection Studies -
Zhang, Xiangian (Vanderbilt University Med Cntr)/ Franke, Adrian (UHCC)
NHBLI 5R01HL095931-03 03/15/10 01/31/14 Phytoestrogen and Endogenous Estrogen Exposure and Risk of Stroke 181,285
Maskarinec, Gertruad NCI 5R25CA090956-09 02/01/01 08/31/13 Nutritional & Behavioral Cancer Prevention in a Multiethnic
Population 521,826
Maskarinec, Gertruad NCI 5R25CA090956-09S1 02/01/01 08/31/13 Nutritional & Behavioral Cancer Prevention in a Multiethnic
Population 105,741
Ramos, Joe NIGMS 3R01GM088266-02S1 09/30/10 08/31/14 RSK2 Regulates Integrin-Mediated Adhesion and Migration 34,127
UHCC Grants Office 01/26/2016
Page 15 of 16
Totals 19,878,036
UHCC Grants Office 01/26/2016
Page 16 of 16
1/27/2016 University of Hawaii Mail Meetings of January 27 and 28
https://mail.google.com/mail/u/0/?ui=2&ik=5a046f4367&view=pt&search=inbox&msg=152814df3d02d5d2&siml=152814df3d02d5d2 1/1
Board of Regents <[email protected]>
Meetings of January 27 and 28
Earl Stoner <[email protected]> Tue, Jan 26, 2016 at 6:18 PMTo: "[email protected]" <[email protected]>
Dear Board of Regents members I am sending this written testimony as I am in S.E Asia on an extended tripand cannot testify at your meetings. I am the immediate past president of the Board of the Friends of the UHCancer Center. As a board member for the past eight years, I am very well acquainted with the new Center andits recent and past history. I believe the comprehensive report recently submitted to you presents a cogent andwell thought out plan and supporting documentation.
This has not always been the case with prior documents released by the UH management team and others.Much unfair criticism has been leveled at the UHCC by parties at Manoa and even some in the epidemiologydepartment of the Cancer Center. Largely this was the result of dissatisfaction with the former director. What Ifound particularly disturbing was the fact that some of those in the UH faculty that felt they were beingmistreated felt they could go directly to the media with their concerns. The result was negative press for theCenter in general which affected the staff and researchers as well as seriously damaging fund raising capability.Clearly, those employees have little respect for the entity that employs them and provides for their livelihood.
I have read the draft report presented to you and find it to be the first truly comprehensive study with factualinformation on the UHCC since it's move into it's new quarters. I hope you will agree and give it the supportnecessary both to back the administration and influence the legislature to continue financial support for theCenter. Let's remember that only five years ago the Board of Regents and the legislature supported a $100million plus bond issue for the development of the new building with the consideration that bioscience,particularly cancer research, was a necessary addition to expanding Hawaii's economy. Has that visionchanged? I think not.
While the report and recommendations require much work, this new Center is and should continued as a fledglingbusiness that needs time and support to succeed. Closing it or otherwise reducing its potential has someonerous concerns for the university. Knee jerk reactions such as those proposed by the Center's opponents arenot solutions and may do more to damage an often impacted university. I hope you will join me and others thatsupport the UH Cancer Center as an important part of our university and our state.
Thank you..... Earl Stoner
1/27/2016 University of Hawaii Mail Written Testimony for Meeting on January 28, 2016, 9:00 a.m.
https://mail.google.com/mail/u/0/?ui=2&ik=5a046f4367&view=pt&search=inbox&msg=15283c28c570eeb7&siml=15283c28c570eeb7 1/1
Board of Regents <[email protected]>
Written Testimony for Meeting on January 28, 2016, 9:00 a.m.
Diane Ono <[email protected]> Wed, Jan 27, 2016 at 5:45 AMTo: [email protected]
Dear Honorable Regents:
Attached please find my submission of written testimony in support of funding for the University of Hawai’iCancer Center. Thank you for considering this.
Sincerely, Diane T. Ono
img160127053349.pdf1137K
